Equity Overview
Price & Market Data
Price: $0.108
Daily Change: $0.00 / 0.00%
Daily Range: $0.108 - $0.114
Market Cap: $2,480,665
Daily Volume: 1,200
Performance Metrics
1 Week: -20.57%
1 Month: 22.92%
3 Months: 23.71%
6 Months: -71.01%
1 Year: -91.63%
YTD: 37.51%
Details
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company's preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series for the treatment of PARP resistant adult and childhood cancers; and kt-4000, a DNA-damaging DDR inhibitors. It has a research collaboration with Variational AI Inc. to identify and develop novel small-molecule therapies against DNA-damage response (DDR) targets for the treatment of cancer. Additionally, it signed a letter of intent with NanoPalm Ltd. to form a joint venture to co-develop novel small-molecule oncology therapeutics. The company was formerly known as Vincero Capital Corp. Rakovina Therapeutics Inc. is headquartered in Vancouver, Canada.